Trials / Completed
CompletedNCT01776437
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMN 673 | 500mcg dose of BMN 673, 2 discrete single doses separated by 21 days |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2013-05-01
- Completion
- 2013-07-01
- First posted
- 2013-01-28
- Last updated
- 2017-07-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01776437. Inclusion in this directory is not an endorsement.